Browse News
Filter News
Found 319 articles
-
Autologous Cell Therapy Market Size to Attain US$ 47.08 Bn by 2033
4/23/2024
The global autologous cell therapy market size was evaluated at US$ 7.99 billion in 2023 and is expected to attain around US$ 47.08 billion by 2033, growing at a CAGR of 19.39% from 2024 to 2033.
-
Primary Cell Culture Market Size to Worth Around USD 21.51 Billion by 2033
4/22/2024
According to Precedence Research, the primary cell culture market size was valued at USD 7.03 billion in 2023 and is expected to be worth around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% from 2024 to 2033.
-
Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033
4/22/2024
The global cell therapy market size was valued at USD 4.85 billion in 2023 and is projected to surpass around USD 37.42 billion by 2033, registering a CAGR of 22.67% over the forecast period of 2024 to 2033 according to Nova One Advisor.
-
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
4/19/2024
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on "Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach" at the Exosomes of Europe conference in London in June, 2024.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
4/18/2024
NRx Pharmaceuticals, Inc. announced that has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550 and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.
-
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
4/18/2024
NRx Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses.
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
4/17/2024
NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
4/15/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
4/8/2024
NRx Pharmaceuticals, Inc. today announced that the Company has achieved data-lock in its Phase 2b /3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101.
-
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update
4/2/2024
NurExone Biologic Inc. today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.
-
Microbiology Testing Market Experiencing Rapid Growth
4/1/2024
The global microbiology testing market size was valued at USD 5.33 billion in 2023 and it is expected to surpass around USD 12.72 billion by 2033 with a CAGR of 9.12% from 2024 to 2033 due to the increasing demand for genetic testing services.
-
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/1/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2023 and provided a business update.
-
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
3/28/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares.
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
3/28/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of its expected annual report to be filed later today.
-
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
3/27/2024
NurExone Biologic Inc., is pleased to announce that, the Company completed a combined exercise and expiration of 12,682,340 common share purchase warrants issued pursuant to a private placement of units that closed on June 15, 2022.
-
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
3/26/2024
NRx Pharmaceuticals, Inc. announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website.
-
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
3/25/2024
NRx Pharmaceuticals, Inc. today announced that Dr. Jonathan Javitt , Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024.
-
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
3/22/2024
NurExone Biologic Inc., a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd., a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies.